(Q35588154)

English

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230

scientific article published on 18 February 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230 (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

Nagalingeswaran Kumarasamy

1

object named as

Nagalingeswaran Kumarasamy

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Mina C Hosseinipour

9

object named as

Mina C Hosseinipour

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Heather J Ribaudo

3

object named as

Heather J Ribaudo

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Carole L Wallis

4

object named as

Carole L Wallis

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sharlaa Badal-Faesen

12

object named as

Sharlaa Badal-Faesen

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Khuanchai Supparatpinyo

11

object named as

Khuanchai Supparatpinyo

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Karin L Klingman

8

object named as

Karin L Klingman

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

2

object named as

Evgenia Aga

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

David Katzenstein

5

object named as

David A Katzenstein

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Wendy S Stevens

6

object named as

Wendy S Stevens

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

10

object named as

John A Crump

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Michael R Norton

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

John A Bartlett

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

18 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1552-1558

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Effect of mobile telephone reminders on treatment outcome in HIV: evidence from a randomised controlled trial in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Drug susceptibility and resistance mutations after first-line failure in resource limited settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Rationale and uses of a public HIV drug-resistance database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Human immunodeficiency virus reverse transcriptase and protease sequence database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

12 July 2018

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

26 September 2018

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4425828

26 September 2018

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

https://pubmed.ncbi.nlm.nih.gov/25694653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/25694653

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/CID/CIV109

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35588154&oldid=1858082924"